[{"orgOrder":0,"company":"WEX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tetrodotoxin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"WEX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"WEX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"WEX Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"WEX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tetrodotoxin","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"WEX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"WEX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"WEX Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dogwood Therapeutics","sponsor":"WEX Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Tetrodotoxin","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Dogwood Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Dogwood Therapeutics \/ Wex Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Dogwood Therapeutics \/ Wex Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals for Tetrodotoxin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : The combined company will be focused on Halneuron, in Phase 2b for chemotherapy-induced neuropathic pain, IMC-1, poised for Phase 3 for fibromyalgia and IMC-2 to treat Long-COVID sequelae.

                          Brand Name : Halneuron

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 07, 2024

                          Lead Product(s) : Tetrodotoxin

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : WEX Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          02

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Halneuron (tetrodotoxin injectable formulation), a selective sodium channel blocker, produces analgesia either by decreasing the propagation of action potentials by sodium channels, being developed for Neuropathic Pain.

                          Brand Name : Halneuron

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 11, 2023

                          Lead Product(s) : Tetrodotoxin

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Halneuron (Tetrodotoxin injectable formulation), a selective sodium channel blocker, produces analgesia either by decreasing the propagation of action potentials by sodium channels and/or by blocking ectopic discharges associated with chronic pain.

                          Brand Name : Halneuron

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 03, 2023

                          Lead Product(s) : Tetrodotoxin

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank